53
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis and evaluation of L-quebrachitol derivatives against platelet aggregation

, , , &
Pages 824-832 | Received 21 Aug 2023, Accepted 28 Feb 2024, Published online: 20 Mar 2024
 

Abstract

Thrombosis plays an important role in the occurrence and development of cardiovascular and cerebrovascular diseases that contribute to high mortality and morbidity in patients. L-(-)-Quebrachitol (QCT), a natural product, was first isolated from quebracho bark. It can inhibit PAF receptor and decrease gastric damage induced by indomethacin, as a drug against platelet aggregation. Here, five QCT derivatives were synthesized and investigated for their inhibitory effects on platelet aggregation. Among them, compound 3a showed anticoagulant effects comparable to aspirin, while compound 4b showed dose-independent inhibitory activities in rats that were stronger than aspirin.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

Project supported by the National Natural Science Foundation of China (No. 82273793), Key Research Project of Department of Education of Liaoning Province (LJKZZ20220108), the China Postdoctoral Science Foundation (No. 2019M661132), the foundation of Liaoning Provincial Department of Education (No. LJKQZ20222351).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.